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Abstract
Background: The cholinergic anti-inflammatory pathway (CAP) is based on vagus nerve (VN) activity that regulates
macrophage and dendritic cell responses in the spleen through alpha-7 nicotinic acetylcholine receptor (a7nAChR)
signaling. Inflammatory bowel disease (IBD) patients present dysautonomia with decreased vagus nerve activity, dendritic
cell and T cell over-activation. The aim of this study was to investigate whether central activation of the CAP alters the
function of dendritic cells (DCs) and sequential CD4+/CD252T cell activation in the context of experimental colitis.
Methods: The dinitrobenzene sulfonic acid model of experimental colitis in C57BL/6 mice was used. Central,
intracerebroventricular infusion of the M1 muscarinic acetylcholine receptor agonist McN-A-343 was used to activate
CAP and vagus nerve and/or splenic nerve transection were performed. In addition, the role of a7nAChR signaling and the
NF-kB pathway was studied. Serum amyloid protein (SAP)-A, colonic tissue cytokines, IL-12p70 and IL-23 in isolated splenic
DCs, and cytokines levels in DC-CD4+CD252T cell co-culture were determined.
Results: McN-A-343 treatment reduced colonic inflammation associated with decreased pro-inflammatory Th1/Th17 colonic
and splenic cytokine secretion. Splenic DCs cytokine release was modulated through a7nAChR and the NF-kB signaling
pathways. Cholinergic activation resulted in decreased CD4+CD252T cell priming. The anti-inflammatory efficacy of central
cholinergic activation was abolished in mice with vagotomy or splenic neurectomy.
Conclusions: Suppression of splenic immune cell activation and altered interaction between DCs and T cells are important
aspects of the beneficial effect of brain activation of the CAP in experimental colitis. These findings may lead to improved
therapeutic strategies in the treatment of IBD.
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Introduction
Inflammatory bowel diseases (IBD) are idiopathic chronic,
recurrent intestinal disorders of complex pathogenesis, which
include Crohn’s disease (CD) and (UC) [1]. The IBD etiopatho-
genesis is multifactorial, involving an aberrant immune response to
gut bacterial antigens that develop in genetically predisposed
individuals [1]. Dysregulated immune responses in the context of
IBD have been therapeutically targeted by biologicals (i.e. anti-
tumor necrosis factor (TNF)-a), corticosteroids and thiopurines
[2]. IBD is reflected by a Th1 and Th17 immune response [3,4],
where the Th2 response seems to play only a minor role [5]. In
line with this paradigm new therapeutics have been currently
studied in clinical settings of IBD [6].
The cholinergic anti-inflammatory pathway (CAP) controls the
production of different Th1 and Th17 cytokine in several
inflammatory models, including experimental colitis [7,8]. In-
creased vagus nerve activity through the release of acetylcholine
(ACh) in the reticuloendothelial system has been associated with
decreased immune cell activation and altered cytokine release
[9,10]. This effect is mainly mediated through the alpha-7
nicotinic acetylcholine receptor (a7nAChR) signaling in antigen
presenting cells [11]. Cellular and molecular mechanisms under-
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lying the CAP and the role of the spleen have been actively
investigated. In addition to electrical vagus nerve (VN) stimulation
[12], this physiological mechanism can be activated in the CNS by
using galantamine, a centrally-acting acetylcholinesterase inhibitor
[9,13,14]. We have previously reported that the central activation
of the CAP inhibits acute inflammation in a murine models of
colitis resembling UC and CD [9]. In this context, treatments with
galantamine ameliorated acute colitis through a dendritic cell
(DC)-mediated mechanism and major histocompatibility complex
(MHC) II regulation. Moreover, in line with the role of a7nAChR
in mediating anti-inflammatory cholinergic signals, we have
demonstrated that an a7nAChR agonist regulates DC interleukin
(IL)-12p40 release [9]. This is consistent with data demonstrating
that in vitro mature spleen DCs that are exposed to nicotine
produce decreased levels of IL-12p40 [15].
IBD is characterized by mucosal recruitment of a variety of
immune inflammatory cells including DCs [1]. A hallmark of IBD
is a marked accumulation of myeloid cells particularly monocytes
and DCs. Accordingly, selective depletion or adhesion blockade of
DCs by Diphtheria Toxin or anti-IL-12 treatment suppress DSS-
colitis [16,17]. DCs are found in the spleen and the intestine where
they are present at the level of the lamina propria, Peyer’s patches
and lymphoid follicles and outside the intestine within the
mesenteric lymph nodes (MLN) [18]. These DCs are in an
‘immature’ state and are unable to stimulate T cells. Although
these DCs lack the required accessory signals for T cell activation,
such as cluster of differentiation (CD) 40, they are in position to
capture antigens (Ag). Once primed, they migrate to the secondary
lymphoid compartments (MLN or spleen) to present Ag-peptide
complexes to naı¨ve CD4+ T cells and CD8+ cytotoxic T cells to
initiate pathology or tolerance via an increase in expression of
MHC II, CD40, CD80 and CD86 co-stimulatory molecules and
an increase in IL-12p70 and IL-23 expression. No only the
expression of the co-stimulating factors can alter T-cell priming,
but the cytokine profile released by the DCs can potentially
regulate T-cell priming.
Although, recent findings have highlighted a key role of the
splenic DCs in mediating vagus nerve anti-inflammatory signaling
during experimental colitis [9], the exact role of a vagus nerve -to
spleen DCs anti-inflammatory axis in the regulation of intestinal
inflammation remained to be further characterized. Thus, the
present study examined the role of the vagus in two models of
colitis induced: i) a lymphocyte-dependent model by intracolonic
administration of 2, 4-dinitrobenzene sulfonic acid (DNBS) [19]
and ii) a semi lymphocyte-independent self-limiting model of
erosive colonic injury and inflammation through oral administra-
tion of dextran sodium sulfate (DSS) [20,21]. Here we studied
whether, in the context of experimental colitis, central activation of
the CAP by an M1mAChR agonist alters T cell priming via
splenic DCs, through an effect mediated by the vagus and the
splenic nerve and the release of DC cytokine. We demonstrate that
central administration of McN-A-343 significantly ameliorates
disease severity and inhibits inflammation in the context of
experimental colitis via a decrease of splenic T cell priming. This
therapeutic efficacy depends on the integrity of the vagus and the
splenic nerve and is mediated through modulation of the
functional interaction between DCs and CD4+CD252T cell via
an a7nAChR and NF-kB signaling, demonstrating the potential
effect of central activation of the CAP in the context of antigen
presenting cell and the important role of cytokine release by DC in
the regulation of T-cell priming.
Materials and Methods
Animals
Male C57BL/6 mice (7–9 weeks old) were purchased from
Charles Rivers (Canada) and maintained in the animal care facility
at the University of Manitoba under specific pathogen-free
conditions. No differences in food intake or body weight were
observed between the groups after vagotomy procedure.
Surgical procedures & drug treatments
Mice were anaesthetized using ketamine (150 mg/kg, i.p;
Wyeth, St Laurent, Canada) and xylazine (10 mg/kg, i.p; Bayer
Inc. Toronto, Canada). I.c.v. implantation of the cannula, splenic
neurectomy (NRX), subdiaphragmatic bilateral vagotomy (VXP),
or splenectomy (SPX) were performed on the same day [9]
(Figure 1). The completeness of vagotomy was verified using the
CCK-8 satiety test [22,23] and via post-mortem inspection of
vagal nerve endings using microscopic observation by using a
Bielschowsky silver staining [24]. The completeness of neurectomy
was verified post-mortem by noradrenaline enzyme-linked immu-
nosorbent assay in sham-operated and NRX animals; a success
rate of 94% was achieved (data not shown). Mice were allowed to
recover for 10 days. One day before initiation of colitis
pharmacological treatment started: micro-osmotic pumps (Alzet,
Cupertino, CA) were connected to cannula and filled with vehicle
(saline) or the McN-A-343 (5 ng/day, Sigma, Mississauga,
Canada) and placed as previously described [9].
Induction of colitis
Two specific models of gut inflammation were used. First we
used the DNBS model of colitis. For the DNBS study, mice were
anaesthetized with IsofluraneH (Abbott, Toronto, Canada). A
10 cm long PE-90 tubing (ClayAdam, Parisppany, NJ), attached to
a tuberculin syringe (BD, Mississauga, Canada), was inserted
(intrarectally) 3.5 cm into the colon. Colitis was induced by intra-
rectal administration of 100 ml of 4 mg of DNBS solution (ICN
Biomedical Inc., Aurora, OH) in 30% ethanol (Sigma) and the
mice left for 3 days [20]. Mice were killed on day 3 and samples
were taken. Control mice (without colitis) received saline
administration. As no effect of the treatment and surgery was
visible using the 30% ethanol group, only the DNBS group is
presented. Alternatively, we used a second model of epithelial
erosion using dextran sulfate sodium (DSS) (molecular weight
[MW], 40 kilodaltons; MP Biomedicals, Soho, OH). DSS was
added to the drinking water in a final concentration of 5% (wt/vol)
for 5 days [21]. Controls were all time-matched and consisted of
mice that received normal drinking water only. Mean DSS
consumption was noted per cage each day. Mice with colitis were
supplied with 6% sucrose (Sigma) in drinking water to prevent
dehydration.
Characterization of inflammation
Colonic samples were collected 3 and 5 days post-DNBS and
DSS activation respectively, and blood was collected by intracar-
diac puncture under isoflurane (Abbot) anaesthesia. Serum
amyloid protein-A (SAP) was used as a marker for systemic
inflammation and was determined using ELISA commercial kit
(R&D Systems, Minneapolis, MN). Colonic samples were homog-
enized in 700 microliter of Tris-HCl buffer containing protease
inhibitors (Sigma). Samples were centrifuged for 30 minutes, and
the supernatant was frozen at 80uC until assay. Cytokine levels
(TNF-a, IL-6, IL-1 b, IFN-c, IL-17, IL-12p70, IL-23 and IL-4)
were determined using an enzyme-linked immunoabsorbant assay
commercial kit (R&D Systems).
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Isolation of splenic CD11c+ cells and culture. Isolation of
splenic CD11c+ cells and culture
3 or 5 days post-activation associated with DNBS or DSS colitis
respectively, the spleens were digested in 2 mg/ml21 collagenase
D (Roche Diagnostics, Meylan, France) in RPMI 1640 (Life
Technologies, Grand Island, NY) for 30 min at 37uC. EDTA
(Sigma) at 5 mM was added during the last 5 min to disrupt DC-T
cell complexes, and the cell suspension was filtered. Total
splenocytes after RBC lysis with ACK lysis buffer (150 mM
NH4Cl, 10 mM KHCO3, 0.1 mM EDTA; Life Technologies)
were incubated with CD11c+ microbeads (Miltenyi Biotec,
Auburn, CA) for 15 min at 48uC. The cells were then washed,
resuspended in cell separation buffer (Dulbecco’s Phosphate-
Buffered Saline [D-PBS] without Ca21 and Mg21 containing 2%
FBS and 2 mM EDTA, (Life Technologies) and passed through
magnetic columns (Miltenyi Biotec) for positive selection. After
passing consecutively through two columns, the collected splenic
CD11c+ cell preparations showed greater than 95% purity.
Splenic CD11c+ cell isolated from different groups of mice were
cultured in complete RPMI 1640 medium (Life Technologies)
containing 10% heat-inactivated FBS, 25 mg/ml21 gentamicin,
2 mM L-glutamine in 12-well plates at 1.10+6 cells/well for 24 hrs,
and the supernatants were measured for IL-12p40, IL-6 and TNF-
a by ELISA (R&D Systems). To characterize the CD11c+ cellular
and intracellular pathway, in a separate set of experiment the
a7nAChR agonist GTS-21 (100 mM; Sigma) or methyllycaconi-
tine (a specific a-7 nicotinic antagonist, 10 mM; Sigma) or betulinic
acid (a specific NF-kB activator, 10 mM; Sigma) or BAY 11-7082
(a specific NF-kB inhibitor, 10 mM; Sigma) were added to
medium.
CD4+CD25- T Cell co-culturing with CD11c+ DCs
Spleen were removed from mice and gently meshed in DMEM
containing 10% FBS (Life Technologies) to prepare for single cell
suspensions. CD4+/CD252 T cells were isolated by the
CD4+CD252 T cell isolation kit (Miltenyi Biotec) according to
manufacturer’s instruction. The purity of CD4+CD252 popula-
tions was around 90%. CD11c+ DCs isolated from colitic mice
receiving the different treatments were cultured for 24 hrs in the
presence or absence of GTS-21 (a specific a7nAChR agonist,
100 mM) before medium was washed and co-cultured with
CD4+CD252 T cell isolated from naı¨ve mice at ratio of 1:3
(DCs:T cells) [25] in plates coated with 10 mg/ml21 of anti-CD3
and 2 mg/ml21 of anti-CD28. In neutralization experiments, these
cultures were treated with 10 mg/ml anti-IL-12p35 or anti-IL-
23p19 (R&D Systems) neutralizing mAb to block the potential
activities of endogenous sources of these cytokines. In a separated
set, recombinant (r) IL-12p70 or rIL-23 protein (25 ng/ml21;
R&D Systems) were added to the cell culture medium. Cell culture
supernatants were collected at 24 hrs, and interferon-gamma
(IFN-c), IL-4 and IL-17 levels were analyzed by ELISA (R&D
Systems).
Statistical analysis
Results are presented as means 6 SEMs. Statistical analysis was
performed using one or two way ANOVA followed by the Tukey-
Kramer multiple comparisons post hoc analysis and a P value of ,
0.05 was considered significant with n = 8 to 12 depending on the
groups tested (Prism 4, GraphPad, La Jolla, CA).
Ethical considerations
All experiments were approved by the University of Manitoba
animal ethics committee (10-073) and conducted under the
Canadian guidelines for animal research.
Figure 1. Experimental protocol. On day 1, mice were anaesthetized using ketamine (150 mg/kg, i.p) and xylazine (10 mg/kg, i.p) and i.c.v.
Placement of the cannula, splenic neurectomy (NRX), subdiaphragmatic bilateral vagotomy (VXP), or splenectomy (SPX) were performed. Mice were
allowed to recover for 10 days. Completeness of vagotomy was verified using the CCK-8 satiety test starting on day 8. On day 11, pharmacological
treatment started: micro-osmotic pumps were connected to cannula and filled with vehicle or the McN-A-343. On day 12, colitis was induced using
two specific models of gut inflammation: 2,4-dinitrobenzene sulfonic acid (DNBS) or dextran sulfate sodium (DSS) models. Colitis was induced by
intra-rectal administration of 100 ml of 4 mg of DNBS solution in 30% ethanol and the mice left for 3 days. Alternatively, DSS was added to the
drinking water in a final concentration of 5% (wt/vol) for 5 days. Controls were all time-matched and consisted of mice that received normal drinking
water only. Colonic samples were collected 3 and 5 days post-DNBS and DSS activation respectively.
doi:10.1371/journal.pone.0109272.g001
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Results
Central muscarinic cholinergic activation decreases
macroscopic score and colonic length via the vagus
nerve and the splenic nerve
First we examined the relation between the central stimulation
and the development of experimental colitis. Infusion with McN-
A-343 (5 ng/kg/day), started one day before induction of DNBS
colitis, decreased the macroscopic scores and increased the length
of colon at day 3 (Figure 2). In addition to its efficacy in DNBS
colitis, McN-A-343 treatment decreased the severity of DSS colitis
(Table 1). These results confirmed the disease-alleviating and
counter-inflammatory effects of centrally-acting M1mAChR
agonist treatments in the two models of colitis. To further study
whether the beneficial effects of central cholinergic activation in
the context of colitis depend on the vagus nerve-to spleen axis we
performed a series of experiments with mice subjected to
vagotomy (VXP), splenic neurectomy (NRX) and/or splenectomy
(SPX). VXP resulted in exacerbation of disease severity (Figure 2)
and this effect was abolished in mice simultaneously subjected to
SPX (Figure 2). The beneficial effects of McN-A-343 on the
macroscopic makers and colon length were abolished in mice with
VXP, SPX, or VXP and SPX (Figure 2). NRX resulted in
comparable to VXP exacerbation of disease severity (Figure 2) and
this effect was abolished in mice simultaneously subjected to SPX
(Figure 2). Furthermore, the beneficial effects of McN-A-343 were
abrogated in mice with NRX, SPX or NRX and SPX (Figure 2).
Similar effects were observed in the context of DSS colitis in the
absence or presence of the vagus and splenic nerves (Table 1).
Central muscarinic cholinergic activation decreases
serum SAP level and colonic Th1/Th17 cytokine release
via the vagus nerve and the splenic nerve
To determine the regulatory effect on colonic Th1-Th2 and
Th17 cytokine profile, IFN-c, IL-17, IL-12p70 IL-23 and IL-4
were studied. McN-A-343 (5 ng/kg/day) treatment, started one
day before induction of DNBS-colitis decreased all colonic
inflammatory markers studied. Decreased severity of colitis in
McN-A-343-treated mice as compared to saline-treated mice was
evident by the 2.1-fold decrease in the SAP levels (Figure 3A). The
increase in colonic in IFN-c was 2.7-fold lower (Figure 3B) and the
up regulation of IL-17 (Figure 3C), IL-12p70 (Figure 3D), and IL-
23 (Figure 3E) were respectively 2.4-fold, 3.1-fold and 2.2-fold
lower. Same pattern of results were found when IL-1 b, IL-6 and
TNF-a were studied (Figure S1). No significant changes were
detected in IL-4 levels (Figure 3F). Similar cytokine alterations
were determined in the context of DSS colitis (Table 1).
VXP resulted in exacerbation of disease severity (Figure 3) and
this effect was abolished in mice simultaneously subjected to SPX
(Figure 3). The beneficial effects of McN-A-343 on SAP cytokine
levels and cytokine were abolished in mice with VXP, SPX, or
VXP and SPX (Figure 3, Figure S1). NRX resulted in comparable
to VXP exacerbation of disease severity (Figure 3, Figure S1) and
this effect was abolished in mice simultaneously subjected to SPX
(Figure 3, Figure S1). Furthermore, the beneficial effects of McN-
A-343 were abrogated in mice with NRX, SPX or NRX and SPX
(Figure 3, Figure S1). Similar effects were observed in the context
of DSS colitis in the absence or presence of the vagus and splenic
nerves (Table 1).
Central cholinergic activation decreases splenic CD11c+
DCs IL-12p70 and IL-23 release via the vagus nerve and
the splenic nerve
To provide further insight into the cellular mechanisms
mediating cholinergic anti-inflammatory effects in the DNBS
model of colitis, we studied the role of splenic CD11c+ DCs. We
found a significant decrease of IL-12p70 and IL-23 in supernatants
of splenic CD11c+ DCs isolated from colitic McN-A-343-infused
mice (Figure 4) as compared to colitic vehicle-treated controls.
Conversely, VXP or NRX treatments increased the two cytokines
and no beneficial effect of McN-A-343 infusion was found in the
absence of an intact vagus nerve or splenic nerve (Figure 4).
Similar effects were observed in the context of DSS colitis in the
Figure 2. Central administration of a M1mAchR agonist
alleviates macroscopic markers of 2, 4-dinitrobenzene sulfonic
acid (DNBS)–induced colitis through vagus nerve and splenic
nerve signaling to the spleen. Vagotomy (VXP) and/or splenectomy
(SPX), splenic neurectomy (NRX) and/or splenectomy (SPX) were
performed 10 days prior to initiating McN-A-343 (5 ng/kg/day, i.c.v.)
treatment and/or colitis induction as described in Material and
Methods. *Sham represents data obtained in sham SPX mice, because
no significant differences were determined between this group and any
other sham group of animals; A: Macroscopic score and B: colon length
were evaluated. Values are shown as means 6 SEM. Samples were
collected on day 3 post-DNBS induction; mice per group$8. aP,0.05 as
compared to sham-saline-DNBS-treated group, bP,0.05 as compared to
VXP-DNBS-treated group or NRX-DNBS-treated group respectively, cP,
0.05 as compared to sham-McN-A-343-DNBS-treated group.
doi:10.1371/journal.pone.0109272.g002
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absence or presence of the vagus and splenic nerves (Table 1). No
effect was detected when IL-4 was studied (data not shown).
DC express a7nAChR, to confirm the role of the a7nAChR at
the splenic level, we isolated splenic CD11c+ DCs from sham-
operated, VXP or NRX DNBS-colitic mice. In colitic mice with
VXP or NRX, addition of GTS-21 (a specific a7nAChR agonists,
100 mM) in the culture medium significantly decreased the
production of IL-12p70 and IL-23 (Figure 4). Conversely, addition
of methyllycaconitine (a specific a7nAChR antagonist, 10 mM) in
the medium reversed the beneficial effect of the GTS-21 treatment
(IL-12p70: Sham 99610; VXP 178614; NRX 165617 pg/ml
and IL-23: Sham 5269; VXP 103612; NRX 96616 pg/ml). No
effect of methyllycaconitine treatment was detectable in Sham,
VXP and NRX groups not treated with GTS-21. No synergistic
affect was observed in CD11c+ DCs isolated from colitic McN-A-
343-infused mice and treated in vitro with GTS-21. No effect on
splenic CD11c+ DCs proliferation was observed (data not shown).
Central cholinergic activation decreases splenic CD11c+
DCs IL-12p70 and IL-23 release via the NF-kB pathway
Previously, an increase of splenic ACh levels after central
activation of the CAP accompanied by a decrease of splenic
CD11c+ DCs IL-12p40 release has been demonstrated [9]. To
provide insight into the transduction pathway by which central
cholinergic activation decreases IL-12p70 and IL-23 in splenic
CD11c+ DCs, we pre-treated isolated splenic CD11c+ DCs from
different groups with an NF-kB activator (betulinic acid) or an
inhibitor (BAY 11-7082) for 24 hours. Using the DNBS model, the
beneficial effect of the in vivo McN-A-343 infusion or ex vivo
treatment with GTS-21 was partially reversed in the presence of
betulinic acid (Figure 5A, B). Conversely, the deleterious effect of
VXP ad NRX was abolished in the presence of BAY 11-7082
(Figure 5C, D). These results highlight the importance of the NF-
kB pathway in splenic CD11c+ DCs as a mediating event of IL-
12p70 and IL-23 release during colitis and its suppression by
central muscarinic cholinergic activation of the vagus nerve -to
spleen axes.
Central cholinergic activation regulates splenic CD11c+
DCs priming of CD4+CD252 T cells via the vagus nerve
and splenic nerve
Recent data demonstrated that the central cholinergic activa-
tion decreases splenic CD11c+ DCs cytokine production and
MHC class II marker and that this effect was dependent on neural
signals along the vagus and the splenic nerve [9]. To demonstrate
the importance of the DC cytokine release vs delivery of co-
stimulatory signals, we studied the T-cell priming function of
splenic CD11c+ DCs. To determine the contribution of
CD4+CD252 T cells to the decreased cytokines production
observed in the spleen following activation of the CAP during
DNBS-induced colitis, we isolated CD4+CD252 T cells from the
spleen of naı¨ve animals and determine the splenic CD11c+ DCs
priming of CD4+CD252 T cells and their subsequent cytokine
release in the presence of anti-CD3/Cd28 Abs. CD4+CD252 T
cells, isolated from naı¨ve mice were co-cultured for 24 h with
splenic CD11c+ DCs isolated from DNBS-colitic mice in vivo
treated with McN-A-343. CD4+CD252 T cells released signifi-
cantly lower amount of IFN-c (Figure 6A), IL-17 (Figure 6B) as
compared to CD4+CD252 T cells co-cultured with splenic
Table 1. Central administration of a M1mAchR agonist alleviates the severity of Dextran sulfate sodium (DSS 5%)–induced colitis.
DSS 5%
Markers Saline McN-A-343 VXP VXP + McN-A-343 NRX NRX + McN-A-343
Macroscopic score (AU) 4.860.3 3.460.4a 7.960.6a 8.360.33a,b 8.460.43a 7.860.7a,c
Colon length (cm) 6.360.4 7.660.6a 5.160.3a 5.460.3a,b 4.960.4a 5.160.6a,c
SAP pg/ml (serum) 54.164.4 37.862.2a 84.262.7a 8762.4a,b 86.963.1a 81.165.1a,c
IFN-c pg/mg protein (colon) 40.962.9 18.761.3a 85.763.6a 78.363.5a,b 8864a 90.566.7a,c
IL-17 pg/mg protein (colon) 6466.6 13.762.5a 141.468a 145.468.2a,b 163.8615a 164.7617a,c
IL-12p70 pg/mg protein (colon) 138.663.7 81.465.1a 219.265.4a 230.267.8a,b 231.668.8a 241.468.7a,c
IL-23 pg/mg protein (colon) 67.364.4 34.866.7a 153.466.5a 161.365.5a,b 15667.6a 165.163.8a,c
IL-4 pg/mg protein (colon) 29.462.3 25.164.4 30.163.3 31.662.48 2564.8 27.263.3
IL-12p70 pg/ml (DC medium) 109.3612.8 43.4610.2a 198.567.5a 19466.4a,b 171618a 183.769.1a,c
IL-23 pg/ml (DC medium) 83.863.1 12.8761.8a 142.6614.3a 165.2612.6a,b 143.166.4a 150.668.2a,c
IFN-c pg/ml (DC:T cell co-culture
medium)
15866165 846644a 25916159a 27146165a,b 26376125a 27286134a,c
IL-17 pg/ml (DC:T cell co-culture
medium)
287.7615.4 142.266.9a 864.6648a 794.9656.1a,b 821.7640.6a 803.7655a,c
IL-4 pg/ml (DC:T cell co-culture
medium)
36.866 44.266.5 4563.8 44.167.6 48.467.9 41.568.9
Vagotomy (VXP) or splenic neurectomy (NRX) were performed 10 days prior to initiating McN-A-343 (5 ng/kg/day, i.c.v.) treatment and/or colitis induction as described
in Material and Methods. Macroscopic score, colon length, serum amyloid protein (SAP), colonic interferon-gamma (IFN-c), interleukin (IL)-17, IL-12p70, IL-23 and IL-4. IL-
12p70 and IL-23 release from splenic CD11c+ dendritic cells (DC). Splenic CD11c+ DCs were isolated from McN-A-343 (5 ng/kg/day, i.c.v. for 6 days)-treated groups of
colitic mice subjected to sham-operation, vagotomy (VXP) or splenic neurectomy (NRX) on day 5 post-colitis induction. Effect of McN-A343 (in vivo) treatment on splenic
CD11c+ DCs function and sequential CD4+ CD252T cell activation. Splenic CD11c+ DCs isolated from different colitic group were cultured in for 24 h before being co-
cultured with CD4+CD252T cells isolated from naı¨ve mice. The levels of IFN-c and IL-17 and IL-4 were measured in media at 24 hrs.
aP,0.05 as compared to sham-saline-DSS-treated group,
bP,0.05 as compared to VXP-DSS-treated group or NRX-DSS-treated group.
cP,0.05 as compared to NRX-DSS-treated group.
doi:10.1371/journal.pone.0109272.t001
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CD11c+ DCs isolated from in vivo saline-treated colitic mice.
Conversely, naı¨ve CD4+CD252 T cells released significantly more
IFN-c and IL-17 when co-cultured with splenic CD11c+ DCs
isolated from vagotomized or neurectomized colitic mice. Similar
effects were observed in the context of DSS colitis in the absence
or presence of the vagus and splenic nerves (Table 1). No
Figure 3. Central administration of a M1mAchR agonist alleviates the severity of 2, 4-dinitrobenzene sulfonic acid (DNBS)–induced
colitis through vagus nerve and splenic nerve signaling to the spleen. Vagotomy (VXP) and/or splenectomy (SPX), splenic neurectomy (NRX)
and/or splenectomy (SPX) were performed 10 days prior to initiating McN-A-343 (5 ng/kg/day, i.c.v.) treatment and/or colitis induction as described in
Material and Methods. *Sham represents data obtained in sham SPX mice, because no significant differences were determined between this group
and any other sham group of animals; A: Serum amyloid protein (SAP); B: Colonic interferon-gamma (IFN-c); C: Colonic interleukin (IL)-17; D: Colonic
IL-12p70; E: Colonic IL-23 and F: Colonic IL-4. Values are shown as means 6 SEM. Samples were collected on day 3 post-DNBS induction; mice per
group $8. aP,0.05 as compared to sham-saline-DNBS-treated group, bP,0.05 as compared to VXP-DNBS-treated group or NRX-DNBS-treated group
respectively, cP,0.05 as compared to sham-McN-A-343-DNBS-treated group.
doi:10.1371/journal.pone.0109272.g003
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beneficial effect of McN-A-343 infusion was found in the absence
of an intact vagus and splenic nerve. None of the treatments had
an effect on the IL-4 levels (Figure 6C).
To evaluate the role of the a7nAChR we used splenic CD11c+
DCs isolated from sham-operated, VXP, and NRX-colitic mice.
At all conditions, DC pretreatment with GTS-21 significantly
decreased the production of IFN-c and IL-17. No synergistic affect
was observed in DCs isolated from colitic McN-A-343 treated
mice and treated in vivo with GTS-21. No drug effect on T-cell
proliferation was observed within a 24 h period of time
(Figure 6D).
Central cholinergic activation regulates splenic CD11c+
DCs priming of CD4+CD252 T cells via IL-12 and IL-23
The p40 subunit is shared by the IL-12 and IL-23 cytokine
[26,27]. To determine the mechanisms by which central
cholinergic activation decrease T-cell priming, co-culture we
treated with anti p19-mAb or p35-mAb. In the presence of anti
p19-mAb, the deleterious effect of VXP ad NRX was abolished in
terms of the IL-17 cytokine profile (Figure 7B) whereas in the
presence of anti p35-mAb only IFN-c levels were affected
(Figure 7A). Conversely, addition of IL-12p70 or IL-23 recombi-
nant proteins restore the level of IFN-c and IL-17 in CD4+CD252
T cells conditioned with splenic CD11c+DCs isolated from colitic
mice treated with McN-A-343 or GTS-21 (Figure 7C, D).
Discussion
Mucosal inflammation in IBD is accompanied by autonomic
nervous system dysfunction with decreased vagus nerve activity
[28]. It is recognized that this autonomic dysfunction plays an
important role in motility and immune response dysregulation
during IBD [29,30]. Over the last decade it has been demonstrat-
ed that the vagus nerve-based CAP has a major anti-inflammatory
function in different inflammatory conditions including colitis and
in models of UC and CD [9,12,31]. While the spleen plays an
important mediating role in the cholinergic anti-inflammatory
pathway [10,32,33], at certain experimental conditions of
intestinal inflammation this physiological mechanism has been
shown to require non neural signaling to spleen [34]. Thus, the
precise mechanisms mediating the impact of the CAP on specific
intestinal inflammation and their cellular and intracellular aspects
remain to de elucidated.
Here, we show that brain mAChR mediated cholinergic
activation results in a decreased susceptibility to experimental
colitis; this effect is vagus nerve- and splenic nerve-dependent and
mediated at a cellular level by a specific interaction between
CD11c+ DCs and CD4+/CD252 T cells.
The DNBS-induced colitis is a widely used model of CD [21]
and is a T-cell dependent model. Depending on the concentration,
the duration, and frequency of DNBS administration, animals
may develop acute or chronic colitis or even colitis-induced
dysplastic lesions. Dysregulated innate and adaptive immune
responses are shown to be important components in colitis
pathogenesis in this model. Recently we demonstrated that brain
stimulation of the CAP alleviates the disease severity and
suppresses colonic proinflammatory cytokine (IL-6, IL-1b and
TNF-a) levels in experimental DSS-induced colitis. Here, after
demonstrating the beneficial effect of central cholinergic activation
by a M1mAChR agonist in DNBS-colitis, we demonstrate that this
effect is accompanied by a downregulation of IFN-c and IL-17,
IL-1 b, IL-6 and TNF-a levels in colonic tissues. The beneficial
effect of the treatment was completely abolished in the absence of
the vagus or the splenic nerves. As the vagus nerve stimulates
gastrointestinal motility, we verified that pharmacological VN
stimulation did not increase diarrhea in our study. In control
group and at the dose used, stool consistency was not affected.
The lack of significant effects of the McN-A-343 infusion on
colonic level of IL-4 in mice DNBS-induced colitis observed in our
study suggests that IL-4 do not play a role in mediating the
beneficial effects of cholinergic modalities on colitis severity, as in
the context of colitis IL-4 is known to decrease T cell priming [35].
This observation is in line with previous data demonstrating the
minor role of vagotomy on IL-4 in colitis [36]. Alternatively, using
a lymphocyte-independent self-limiting model of erosive colonic
Figure 4. Central administration of a M1mAChR agonist
alleviates splenic CD11c+ dendritic cells (DCs) interleukin (IL)-
12p70 and IL-23 release in the context of 2, 4-dinitrobenzene
sulfonic acid (DNBS)–induced colitis through vagus nerve and
splenic nerve signaling to the spleen. A: IL-12p70 and B: IL-23
production from splenic CD11c+ DCs. Splenic CD11c+ DCs were isolated
from control and McN-A-343 (5 ng/kg/day, i.c.v. for 4 days)-treated
groups of colitic mice subjected to sham-operation, vagotomy (VXP) or
splenic neurectomy (NRX) on day 3 post-DNBS induction incubated ex
vivo or not with GTS-21 (a specific a7nAChR agonist, 100 mM). IL-12p70
and IL-23 were measured in media at 24 hrs following treatments.
Values are shown as means 6 SEM, 3 independent experiments with 4
mice per group. aP,0.05 as compared to DNBS-control group, bP,0.05.
doi:10.1371/journal.pone.0109272.g004
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injury and inflammation through oral administration of DSS22, 23,
we demonstrated similar results.
Although previous studies have implicated a key role of splenic
DCs [9,37] and T cells [32] in the context of the CAP, it was not
clear whether alterations in antigen presenting cell response and T
cells priming play any mediating role in the cholinergic regulation
of gut inflammation. We have recently demonstrated an increase
of splenic IL-12p40 after pharmacological stimulation of the vagus
nerve [9]. The fact that the p40 subunit is commonly shared by
IL-12p70 and IL-23 [26,27] prompted us to study IL-12p70 and
IL-23 levels. Alleviated inflammation in DNBS-induced colitis was
accompanied by reduced level of IL-12p70 and IL-23 in the colon
and from splenic CD11c+ DCs isolated from colitic mice treated
with McN-A-343. Conversely, we also observed that colon and
CD11c+ DCs isolated from group without an intact vagus nerve
and splenic nerve produced significantly more IL-12p70 and IL-23
and that the beneficial effect of the MCN-A-343 treatment was
abolished in the absence of the vagus and splenic nerves.
Moreover, in vitro stimulation with a specific a7nAChR agonist
decreased IL-12p70 and IL-23 production of CD11c+ DCs
isolated from both groups. This is in accordance with data
demonstrating a downregulation of IL-12p70 and IL-23 in
polymorphonuclear neutrophils treated with nicotine [38], the
close relation between the splenic nerve and the DC population
within the spleen [39] and splenic Ach release after splenic nerve
stimulation [10]. In our models, it is possible that mesenteric
Figure 5. Implication of the NF-kB pathway in splenic CD11c+ dendritic cells (DCs) cytokine release in the context of 2, 4-
dinitrobenzene sulfonic acid (DNBS)–induced colitis. Interleukin (IL)-12p70 and IL-23 production from splenic CD11c+ DCs. Splenic CD11c+
DCs were isolated from control and McN-A-343 (5 ng/kg/day, i.c.v. for 4 days)-treated groups of colitic mice subjected to sham-operation, vagotomy
(VXP) or splenic neurectomy (NRX) on day 3 post-DNBS induction incubated ex vivo or not with GTS-21 (a specific a7nAChR agonist, 100 mM) or with
A, B: betulinic acid (a specific NF-kB activator, 10 mM) or C, D: BAY 11-7082 (a specific NF-kB inhibitor, 10 mM). IL-12p70 and IL-23 were measured in
media at 24 hrs following treatments. Values are shown as means 6 SEM, 3 independent experiments with 4 mice per group. aP,0.05 as compared
to DNBS-control group, *P,0.05.
doi:10.1371/journal.pone.0109272.g005
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lymphoid or lamina propria DCs may also be involved in
mediating cholinergic effects in the context of colitis, but our data
demonstrate the role of splenic CD11C
+ cells. However, the
possible contribution of other circulating immune cell expressing
the a7nAChR need also be considered, as it has been reported
that a7AChR are expressed not only on DCs but also on other
immune cells including monocytes [40,41], polymorphonuclear
neutrophils [42], B cells [43] and T cells [44]. Further experiments
need to be conduced to decipher the exact role of these cell-types.
NF-kB, an important transcription factor mediating the
proinflammatory cytokine production is attributed to the initiation
and progression of colonic inflammation in mice and humans
[45,46]. nAChRs are expressed on antigen presenting cell
including macrophages and DCs [40], and ACh and nicotine
inhibit TNF-a and NF-kB production from lipopolysaccharide
(LPS)-stimulated human macrophages and splenocytes [47]. In the
context of polymorphonuclear neutrophil activation, it has also
been described that GTS-21 can inhibit phosphorylation and
subsequent degradation of I-kB, which is likely to suppress NF-kB
activation [48]. As nAChRs are expressed on DCs [40], we tested
the role of the intracellular NF-kB pathway. Increased production
of IL-12p70 and IL-23 by DCs in VXP- and NRX mice was
significantly inhibited in the presence of the NF-kB pathway
inhibitor. Moreover, in the presence of NF-kB pathway activator
the levels of both cytokines were increased in CD11c+ DCs
isolated from stimulated groups. In vitro stimulation with GTS-21
decreased IL-12p70 and IL-23 production of CD11c+ DCs
isolated from both group and this effect was abolished in the
presence of the NF-kB activator. Together, these findings indicate
that deactivation of the NF-kB signaling pathway is essential for
pharmacological cholinergic stimulation to inhibit DCs activation,
which is critical in the pathogenesis of colitis in this model. This
corroborates data demonstrating that in vitro mature spleen DCs
that are exposed to nicotine produce decreased levels of IL-12 and
display reduced ability to induce T cell responses [15].
Our results further demonstrate that CD11c+ DCs isolated from
DNBS-colitic mice treated with McN-A-343 have significantly
reduced ability to stimulate naı¨ve CD4+CD252 T cells in vitro to
produce IFN-c and IL-17 as compared to the CD11c+ DCs
isolated from colitic non-treated mice. Moreover, our data
demonstrate, that using the antiCD3/CD28 stimulation model,
the cytokine released by the DC are sufficient to direct T-cell
Figure 6. Role of the CD11c+ dendritic cells (DCs) in CD4+CD252 T cells priming in the context of 2, 4-dinitrobenzene sulfonic acid
(DNBS)–induced colitis. Effect of McN-A343 (in vivo) and GTS-21 (ex vivo) treatments on splenic CD11c+ DCs function and sequential CD4+CD252T
cell activation. Splenic CD11c+ DCs were isolated from control and McN-A-343 (5 ng/kg/day, i.c.v. for 4 days)-treated groups of colitic mice subjected
to sham-operation, vagotomy (VXP) or splenic neurectomy (NRX) on day 3 post-DNBS induction and were cultured in the presence or absence of
GTS-21 (a specific a7nAChR agonist, 100 mM) for 24 hrs before medium was washed and co-cultured with CD4+/CD252 T cells isolated from naı¨ve
mice. The level of A: Interferon-gamma (IFN-c); B: Interleukin (IL)-17 and C: IL-4 were measured in media at 24 hrs; D: CD4+CD252 T cells proliferation.
aP,0.05 as compared to DNBS-control group, bP,0.05, n = 8, data are representative of 3 independent experiments with quadruplicated cultures,
mean 6 SEM.
doi:10.1371/journal.pone.0109272.g006
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priming. This observation provides direct evidence of the
importance of DCs in colitis. It is in agreement with studies in
the context of experimental colitis [16] demonstrating ameliora-
tion of colitis by depletion of DCs after administration of
diphtheria toxin in CD11c-DT receptor transgenic mice [17].
The clinical relevance of these findings is substantiated by previous
data demonstrating that IBD is characterized by increased
expression of innate (IL-12, IL-23) and adaptive (IFN-c, IL-17)
proinflammatory cytokines [5], and Th1, Th17 polarization is
mainly controlled by the IL-12p70 and IL-23 cytokine family
produced by activated DCs [49]. Increased numbers of MDC8+
monocytes, which are the precursors of mucosal DC populations,
are found in patients with IBD and, hence, anti-TNF treatment
results in reduced DCs activation [50]. Moreover, in the context of
IBD, DCs are increased within the lamina propria and peripheral
blood [51] and DCs isolated from peripheral blood monocytes are
potent immune response stimulators [52].
We also further identify the mediating role of IL-12p70 and IL-
23 on DCs/T cell priming. In the absence of an intact vagus or
splenic nerve the presence of a specific anti-p35 Ab decreased
exclusively IFN-c release from T cells. Conversely, in the presence
of anti-p19 Ab only the IL-23 levels were affected. This
corroborates clinical and experimental data demonstrating an
increase in IL-12p40, IL-12p70 and IL-23p19 in intestinal tissue
[53,54]. A beneficial effect of anti p40 or p19 mAbs on human and
experimental colitis has been proposed [55,56]. IL-12 and IL-23
that share the same p40 subunit may play distinct roles in colitis,
depending on the mechanism involved. IL-23p19-deficient mice
develop severe colitis in IL-10 deficient mice [57] and IL-12p35
deficient mice develop a mild colitis [58]. These somewhat
conflicting observations suggest diverse roles of IL-12 and IL-23 in
colitis depending on the model used. Here, we highlight the role of
brain pharmacological activation of the CAP in controlling T cell
priming via DC deactivation and the specific mediating role of IL-
12 and IL-23. In addition, these studies show the efficacy of this
approach in suppressing proinflammatory cytokine production
from DCs through an NF-kB intracellular mechanism and
sequential T-cell instigation.
It is possible that in addition to the spleen the vagus nerve-based
CAP signals in other organs implicated in the development of
colonic inflammation [59]. As in human the VN does not
innervate the distal colon, is also conceivable that other, vagus
Figure 7. Implication of the interleukin (IL)-12p70 and IL-23 pathways during CD4+CD252 T cells priming by splenic CD11c+
dendritic cells (DCs) in the context of 2, 4-dinitrobenzene sulfonic acid (DNBS)–induced colitis. Splenic CD11c+ DCs isolated from
different colitic group were cultured in for 24 h before being co-cultured with CD4+/CD252 T cells isolated from naı¨ve mice in the presence or
absence of A, B: anti-p19 mAb (10 ug/ml21) or anti-p35 mAb (10 ug/ml21); C, D: recombinant (r)IL-12p70 (25 ng/ml21) or rIL-23 (25 ng/ml21) protein.
Supernatant were collected after 24 h. The levels of interferon-gamma (IFN-c) and IL-17 in the culture supernatant were investigated at 24 hrs. *P,
0.05, data are representative of 3 independent experiments with quadruplicated cultures, mean 6 SEM.
doi:10.1371/journal.pone.0109272.g007
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nerve-related factors may play a role in the context of IBD, as the
vagus nerve influences gastrointestinal motility and controls the
ileocecal valve in several species [60,61]. A central potential
activation of the HPA axis associated with a decreased colonic
inflammation cannot been excluded [62].
Our findings provide new insight into the mechanisms of
regulation of mucosal inflammation by brain activation of the
CAP. It is interesting to note that another pharmacological brain
activator of the CAP - CNI-1493 (semapimod), an inhibitor of p38
mitogen-activated protein kinase [63], has now been clinically
tested in patients with CD [64]. This demonstrates, that the
activation of the VN in the context of the anti-inflammatory
pathway might be efficient in IBD patients. A recent case report
published the group of Prof. Bonaz, demonstrated the therapeutic
long-term effects of low frequency vagus nerve stimulation on
EEG and heart rate variability in CD. In this context the patient
presented a significant clinical improvement, with a progressive
decrease of the CDAI score and an endoscopic remission at month
12, associated to an increase of the parasympathetic tone [65].
Moreover, complementary medicine such as cognitive behavioral
therapies or hypnosis, known to modify vagal would be of interest
[66–69].
Our study contributes to better understanding of the pathogen-
esis of colitis and provides novel information related to vagus
nerve-to spleen immune regulation by highlighting a key role for
DCs-T-cell priming. Our findings foster consideration of the
relationship between brain cholinergic activation and disease
activity in patients with IBD and suggest further development of
centrally-acting selective M1mAChR agonists as novel experi-
mental therapeutics in colitis, or alternatively methods to increase
the VN outflow (e.g. electrical VN stimulation, or alternative
medicine).
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nist alleviates the severity of 2, 4 dinitrobenzene sulfonic
acid (DNBS)–induced colitis through vagus nerve and
splenic nerve signaling to the spleen. Vagotomy (VXP)
and/or splenectomy (SPX), splenic neurectomy (NRX) and/or
splenectomy (SPX) were performed 10 days prior to initiating
McN-A-343 (5 ng/kg/day, i.c.v.) treatment and/or colitis induc-
tion as described in Material and Methods. *Sham represents data
obtained in sham SPX mice, because no significant differences
were determined between this group and any other sham group of
animals; A: Colonic interleukin (IL)-17; B: Colonic IL-16; C:
Colonic Tumor necrosis factor (TNF)-alpha. Values are shown as
means 6 SEM. Samples were collected on day 3 post-DNBS
induction; mice per group 8. aP,0.05 as compared to sham-
saline-DNBS-treated group, bP,0.05 as compared to VXP-
DNBS-treated group or NRX-DNBS-treated group respectively,
cP,0.05 as compared to sham-McN-A-343-DNBS-treated group.
(TIFF)
Author Contributions
Conceived and designed the experiments: JEG. Performed the experi-
ments: PM MR JEG. Analyzed the data: PM MR JEG. Contributed
reagents/materials/analysis tools: KJT VAP. Wrote the paper: EK.
References
1. Bernstein CN, Papineau N, Zajaczkowski J, Rawsthorne P, Okrusko G, et al.
(2000) Direct hospital costs for patients with inflammatory bowel disease in a
Canadian tertiary care university hospital. Am J Gastroenterol 95: 677–683.
2. Han X, Benight N, Osuntokun B, Loesch K, Frank SJ, et al. (2007) Tumour
necrosis factor alpha blockade induces an anti-inflammatory growth hormone
signalling pathway in experimental colitis. Gut 56: 73–81.
3. Monteleone I, Pallone F, Monteleone G (2011) Th17-related cytokines: new
players in the control of chronic intestinal inflammation. BMC Med 9: 122.
4. Strober W, Fuss IJ (2011) Proinflammatory cytokines in the pathogenesis of
inflammatory bowel diseases. Gastroenterology 140: 1756–1767.
5. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK (2008) Role of
cytokines in inflammatory bowel disease. World J Gastroenterol 14: 4280–4288.
6. Perrier C, Rutgeerts P (2011) Cytokine blockade in inflammatory bowel diseases.
Immunotherapy 3: 1341–1352.
7. Galitovskiy V, Qian J, Chernyavsky AI, Marchenko S, Gindi V, et al. (2011)
Cytokine-induced alterations of alpha7 nicotinic receptor in colonic CD4 T cells
mediate dichotomous response to nicotine in murine models of Th1/Th17-
versus Th2-mediated colitis. J Immunol 187: 2677–2687.
8. Ghia JE, Park AJ, Blennerhassett P, Khan WI, Collins SM (2011) Adoptive
transfer of macrophage from mice with depression-like behavior enhances
susceptibility to colitis. Inflamm Bowel Dis 17: 1474–1489.
9. Ji H, Rabbi MF, Labis B, Pavlov VA, Tracey KJ, et al. (2013) Central
cholinergic activation of a vagus nerve-to-spleen circuit alleviates experimental
colitis. Mucosal Immunol doi: 10.1038/mi.2013.52.
10. Rosas-Ballina M, Olofsson PS, Ochani M, Valdes-Ferrer SI, Levine YA, et al.
(2011) Acetylcholine-Synthesizing T Cells Relay Neural Signals in a Vagus
Nerve Circuit. Science 334: 98–101.
11. Borovikova LV, Ivanova S, Nardi D, Zhang M, Yang H, et al. (2000) Role of
vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation.
Auton Neurosci 85: 141–147.
12. Meregnani J, Clarencon D, Vivier M, Peinnequin A, Mouret C, et al. (2011)
Anti-inflammatory effect of vagus nerve stimulation in a rat model of
inflammatory bowel disease. Auton Neurosci 160: 82–89.
13. Lee ST, Chu K, Jung KH, Kang KM, Kim JH, et al. (2010) Cholinergic anti-
inflammatory pathway in intracerebral hemorrhage. Brain Res 1309: 164–171.
14. Pavlov VA, Ochani M, Gallowitsch-Puerta M, Ochani K, Huston JM, et al.
(2006) Central muscarinic cholinergic regulation of the systemic inflammatory
response during endotoxemia. Proc Natl Acad Sci U S A 103: 5219–5223.
15. Nouri-Shirazi M, Tinajero R, Guinet E (2007) Nicotine alters the biological
activities of developing mouse bone marrow-derived dendritic cells (DCs).
Immunol Lett 109: 155–164.
16. Abe K, Nguyen KP, Fine SD, Mo JH, Shen C, et al. (2007) Conventional
dendritic cells regulate the outcome of colonic inflammation independently of T
cells. Proc Natl Acad Sci U S A 104: 17022–17027.
17. Berndt BE, Zhang M, Chen GH, Huffnagle GB, Kao JY (2007) The role of
dendritic cells in the development of acute dextran sulfate sodium colitis.
J Immunol 179: 6255-6262.
18. Iwasaki A (2007) Mucosal dendritic cells. Annu Rev Immunol 25: 381-418.
19. Sturiale S, Barbara G, Qiu B, Figini M, Geppetti P, et al. (1999) Neutral
endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P. Proc
Natl Acad Sci U S A 96: 11653-11658.
20. Elson CO, Sartor RB, Tennyson GS, Riddell RH (1995) Experimental models
of inflammatory bowel disease. Gastroenterology 109: 1344-1367.
21. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, et al. (1990) A
novel method in the induction of reliable experimental acute and chronic
ulcerative colitis in mice. Gastroenterology 98: 694-702.
22. Ghia JE, Blennerhassett P, Kumar-Ondiveeran H, Verdu EF, Collins SM (2006)
The vagus nerve: a tonic inhibitory influence associated with inflammatory
bowel disease in a murine model. Gastroenterology 131: 1122-1130.
23. Joyner K, Smith GP, Gibbs J (1993) Abdominal vagotomy decreases the
satiating potency of CCK-8 in sham and real feeding. Am J Physiol 264: R912-
916.
24. Rosenwald A, Reusche E, Ogomori K, Teichert HM (1993) Comparison of
silver stainings and immunohistology for the detection of neurofibrillary tangles
and extracellular cerebral amyloid in paraffin sections. Acta Neuropathol (Berl)
86: 182–186.
25. Murugaiyan G, Mittal A, Weiner HL (2010) Identification of an IL-27/
osteopontin axis in dendritic cells and its modulation by IFN-gamma limits IL-
17-mediated autoimmune inflammation. Proc Natl Acad Sci U S A 107:
11495–11500.
26. Brombacher F, Kastelein RA, Alber G (2003) Novel IL-12 family members shed
light on the orchestration of Th1 responses. Trends Immunol 24: 207–212.
27. Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and
adaptive immunity. Nat Rev Immunol 3: 133–146.
28. Bonaz BL, Bernstein CN (2013) Brain-gut interactions in inflammatory bowel
disease. Gastroenterology 144: 36–49.
29. Hasler WL (2011) Traditional thoughts on the pathophysiology of irritable bowel
syndrome. Gastroenterol Clin North Am 40: 21–43.
30. Irwin MR, Miller AH (2007) Depressive disorders and immunity: 20 years of
progress and discovery. Brain Behav Immun 21: 374–383.
31. Van Der Zanden EP, Boeckxstaens GE, de Jonge WJ (2009) The vagus nerve as
a modulator of intestinal inflammation. Neurogastroenterol Motil 21: 6–17.
Central Cholinergic Activation in Experimental Colitis
PLOS ONE | www.plosone.org 11 October 2014 | Volume 9 | Issue 10 | e109272
32. Karimi K, Bienenstock J, Wang L, Forsythe P (2010) The vagus nerve modulates
CD4+ T cell activity. Brain Behav Immun 24: 316–323.
33. Huston JM, Ochani M, Rosas-Ballina M, Liao H, Ochani K, et al. (2006)
Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal
endotoxemia and polymicrobial sepsis. J Exp Med 203: 1623–1628.
34. Matteoli G, Gomez-Pinilla PJ, Nemethova A, Di Giovangiulio M, Cailotto C, et
al. (2013) A distinct vagal anti-inflammatory pathway modulates intestinal
muscularis resident macrophages independent of the spleen. Gut doi: 10.1136/
gutjnl-2013-304676.
35. Szabo SJ, Dighe AS, Gubler U, Murphy KM (1997) Regulation of the
interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1)
and Th2 cells. J Exp Med 185: 817–824.
36. Ghia JE, Blennerhassett P, El-Sharkawy RT, Collins SM (2007) The protective
effect of the vagus nerve in a murine model of chronic relapsing colitis.
Am J Physiol Gastrointest Liver Physiol 293: G711–718.
37. Valdes-Ferrer SI, Rosas-Ballina M, Olofsson PS, Chavan S, Tracey K (2010)
Vagus Nerve Stimulation Produces an Anti-Inflammatory Monocyte Phenotype
in Blood. Journal of Immunology 184: 138.125.
38. Kroening PR, Barnes TW, Pease L, Limper A, Kita H, et al. (2008) Cigarette
smoke-induced oxidative stress suppresses generation of dendritic cell IL-12 and
IL-23 through ERK-dependent pathways. J Immunol 181: 1536–1547.
39. Prinz M, Heikenwalder M, Junt T, Schwarz P, Glatzel M, et al. (2003)
Positioning of follicular dendritic cells within the spleen controls prion
neuroinvasion. Nature 425: 957–962.
40. Kawashima K, Yoshikawa K, Fujii YX, Moriwaki Y, Misawa H (2007)
Expression and function of genes encoding cholinergic components in murine
immune cells. Life Sci 80: 2314–2319.
41. Yoshikawa H, Kurokawa M, Ozaki N, Nara K, Atou K, et al. (2006) Nicotine
inhibits the production of proinflammatory mediators in human monocytes by
suppression of I-kappaB phosphorylation and nuclear factor-kappaB transcrip-
tional activity through nicotinic acetylcholine receptor alpha7. Clin Exp
Immunol 146: 116–123.
42. Su X, Matthay MA, Malik AB (2010) Requisite role of the cholinergic alpha7
nicotinic acetylcholine receptor pathway in suppressing Gram-negative sepsis-
induced acute lung inflammatory injury. J Immunol 184: 401–410.
43. Koval LM, Yu Lykhmus O, Omelchenko DM, Komisarenko SV, Skok MV
(2009) The role of alpha7 nicotinic acetylcholine receptors in B lymphocyte
activation. Ukr Biokhim Zh 81: 5–11.
44. Razani-Boroujerdi S, Boyd RT, Davila-Garcia MI, Nandi JS, Mishra NC, et al.
(2007) T cells express alpha7-nicotinic acetylcholine receptor subunits that
require a functional TCR and leukocyte-specific protein tyrosine kinase for
nicotine-induced Ca2+ response. J Immunol 179: 2889–2898.
45. MacDermott RP (1994) Alterations in the mucosal immune system in ulcerative
colitis and Crohn’s disease. Med Clin North Am 78: 1207–1231.
46. Neurath MF, Becker C, Barbulescu K (1998) Role of NF-kappaB in immune
and inflammatory responses in the gut. Gut 43: 856–860.
47. Czura CJ, Tracey KJ (2005) Autonomic neural regulation of immunity. J Intern
Med 257: 156–166.
48. Vukelic M, Qing X, Redecha P, Koo G, Salmon JE (2013) Cholinergic receptors
modulate immune complex-induced inflammation in vitro and in vivo.
J Immunol 191: 1800–1807.
49. Hart AL, Al-Hassi HO, Rigby RJ, Bell SJ, Emmanuel AV, et al. (2005)
Characteristics of intestinal dendritic cells in inflammatory bowel diseases.
Gastroenterology 129: 50–65.
50. de Baey A, Mende I, Riethmueller G, Baeuerle PA (2001) Phenotype and
function of human dendritic cells derived from M-DC8(+) monocytes.
Eur J Immunol 31: 1646–1655.
51. te Velde AA, van Kooyk Y, Braat H, Hommes DW, Dellemijn TA, et al. (2003)
Increased expression of DC-SIGN+IL-12+IL-18+ and CD83+IL-12-IL-18-
dendritic cell populations in the colonic mucosa of patients with Crohn’s disease.
Eur J Immunol 33: 143–151.
52. Ikeda Y, Akbar F, Matsui H, Onji M (2001) Characterization of antigen-
presenting dendritic cells in the peripheral blood and colonic mucosa of patients
with ulcerative colitis. Eur J Gastroenterol Hepatol 13: 841–850.
53. Becker C, Wirtz S, Blessing M, Pirhonen J, Strand D, et al. (2003) Constitutive
p40 promoter activation and IL-23 production in the terminal ileum mediated
by dendritic cells. J Clin Invest 112: 693–706.
54. Verdier J, Begue B, Cerf-Bensussan N, Ruemmele FM (2012) Compartmental-
ized expression of Th1 and Th17 cytokines in pediatric inflammatory bowel
diseases. Inflamm Bowel Dis 18: 1260–1266.
55. Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, et al. (2007)
Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model
in mice. Gastroenterology 132: 2359–2370.
56. Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, et al. (2004) A
phase I study evaluating the safety, pharmacokinetics, and clinical response of a
human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol
123: 1037–1044.
57. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, et al. (2006) IL-23 is
essential for T cell-mediated colitis and promotes inflammation via IL-17 and
IL-6. J Clin Invest 116: 1310–1316.
58. Camoglio L, Juffermans NP, Peppelenbosch M, te Velde AA, ten Kate FJ, et al.
(2002) Contrasting roles of IL-12p40 and IL-12p35 in the development of
hapten-induced colitis. Eur J Immunol 32: 261–269.
59. Gottwald TP, Lhotak S, Stead RH (1995) Effects of subdiaphragmatic vagotomy
on mucosal mast cell densities in stomach and jejunum of rats. Adv Exp Med
Biol 371A: 303–306.
60. Dapoigny M, Cowles VE, Zhu YR, Condon RE (1992) Vagal influence on
colonic motor activity in conscious nonhuman primates. Am J Physiol 262:
G231–236.
61. Pahlin PE, Kewenter J (1976) The vagal control of the ileo-cecal sphincter in the
cat. Acta Physiol Scand 96: 433–442.
62. Bonaz B (2013) Inflammatory bowel diseases: a dysfunction of brain-gut
interactions? Minerva Gastroenterol Dietol 59: 241–259.
63. The F, Cailotto C, van der Vliet J, de Jonge WJ, Bennink RJ, et al. (2011)
Central activation of the cholinergic anti-inflammatory pathway reduces surgical
inflammation in experimental post-operative ileus. Br J Pharmacol 163: 1007–
1016.
64. Dotan I, Rachmilewitz D, Schreiber S, Eliakim R, van der Woude CJ, et al.
(2010) A randomised placebo-controlled multicentre trial of intravenous
semapimod HCl for moderate to severe Crohn’s disease. Gut 59: 760–766.
65. Clarenc¸on D, Pellissier S, Sinniger V, Kibleur A, Hoffman D, et al. (2014) Long
Term Effects of Low Frequency (10 Hz) Vagus Nerve Stimulation on EEG and
Heart Rate Variability in Crohn’s Disease: A Case Report. Brain Stimulation In
press.
66. Huang ST, Chen GY, Lo HM, Lin JG, Lee YS, et al. (2005) Increase in the
vagal modulation by acupuncture at neiguan point in the healthy subjects.
Am J Chin Med 33: 157–164.
67. Kubota Y, Sato W, Toichi M, Murai T, Okada T, et al. (2001) Frontal midline
theta rhythm is correlated with cardiac autonomic activities during the
performance of an attention demanding meditation procedure. Brain Res Cogn
Brain Res 11: 281–287.
68. Paul-Labrador M, Polk D, Dwyer JH, Velasquez I, Nidich S, et al. (2006) Effects
of a randomized controlled trial of transcendental meditation on components of
the metabolic syndrome in subjects with coronary heart disease. Arch Intern
Med 166: 1218–1224.
69. Sakai S, Hori E, Umeno K, Kitabayashi N, Ono T, et al. (2007) Specific
acupuncture sensation correlates with EEGs and autonomic changes in human
subjects. Auton Neurosci 133: 158–169.
Central Cholinergic Activation in Experimental Colitis
PLOS ONE | www.plosone.org 12 October 2014 | Volume 9 | Issue 10 | e109272
